Dermaren Sub Q with Lidocaine 1ml

Dermaren

Dermal filler

Deep volume hyaluronic acid filler

Class III CE Marked medical device under EU medical device regulations (EU MDD for dermaren SUB Q with lidocaine).
Listed in EU UDI database with manufacturer RFBio Co., Ltd., South Korea.
Dermaren range documented as CE Certified cross Linked hyaluronic acid filler line for facial contouring and volumisation.

Class III CE Marked medical device under EU medical device regulations (EU MDD for dermaren SUB Q with lidocaine).
Listed in EU UDI database with manufacturer RFBio Co., Ltd., South Korea.
Dermaren range documented as CE Certified cross Linked hyaluronic acid filler line for facial contouring and volumisation.

Deep volume hyaluronic acid filler

Description

Dermaren Sub-Q with Lidocaine 1ml is a high-performance, deeply volumising hyaluronic acid dermal filler for the correction of deep static wrinkles and restoration of facial volume. Formulated with 24 mg/ml of highly cross-linked, non-animal hyaluronic acid and 0.3% lidocaine, it is designed for deep-tissue injections and facial contouring, including cheek and jawline enhancement. Its monophasic, spherical HA structure enables smooth, even distribution within the tissue, delivering natural-looking, long-lasting results and improved hydration.

Bnefits

Provides deep volumising correction for pronounced static wrinkles and folds.
Restores lost facial volume and supports structural contour in mid- and lower face.
Suitable for cheek augmentation and jawline contouring to enhance facial definition.
Contains 24 mg/ml highly cross-linked hyaluronic acid for robust lifting and support.
Includes 0.3% lidocaine to reduce discomfort and improve treatment tolerability.
Monophasic, spherical HA structure allows smooth, even filling and natural results.
Hydrates the skin from within by attracting and retaining water in the dermis.
Professional-grade formulation offering long-lasting outcomes, typically up to 12–18 months.

Indications

Deep static wrinkles (e.g. deep nasolabial folds, marionette lines).
Facial volume loss in midface and other structurally important areas.
Cheek contouring and restoration of malar volume.
Jawline contouring and lower face definition.
Deep facial lines and furrows in areas such as forehead and perioral region, as appropriate for Sub-Q depth.

Composition

Cross-linked hyaluronic acid 24 mg/ml (non-animal origin).
Lidocaine hydrochloride 0.3%.
Physiological buffer solution and excipients (q.s. to 1 ml).

Formulation

Monophasic, highly cross-linked hyaluronic acid soft tissue filler.
Non-animal, stabilised HA with spherical, uniform gel structure.
Injectable sterile, pyrogen-free, transparent viscoelastic gel for deep dermal and subcutaneous use.

Packaging

1 pre-filled sterile syringe × 1 ml Dermaren Sub-Q with Lidocaine.
2 sterile 27G needles (typical configuration with 1 ml syringe, depending on distributor).
Blister-packed syringe and needles in an individual carton with product labelling and instructions for use.

Usage

For professional use only by appropriately trained medical or aesthetic practitioners.
Indicated injection depth is typically deep dermis to subcutaneous or supraperiosteal plane, depending on treatment area and technique.
Prior to injection, cleanse and disinfect the treatment area, and examine anatomy carefully to avoid vascular structures.
Inject slowly using linear threading, fanning or bolus techniques suitable for deep volume restoration and contouring.
Massage gently if required to ensure even distribution and smooth contours, avoiding overcorrection.
Use each syringe for a single patient only; do not resterilise or reuse.
Follow local guidelines and manufacturer’s instructions for maximum dose per session and retreatment intervals.

Contraindications

Hypersensitivity or allergy to hyaluronic acid, lidocaine or other amide-type local anaesthetics, or any component of the product.
History of severe anaphylactic reactions or multiple severe allergies.
Presence of active skin infection, inflammation, herpes lesions or open wounds at or near the intended injection site.
Autoimmune diseases or severe immune disorders, unless carefully evaluated by a physician.
Bleeding disorders or current use of anticoagulant or antiplatelet therapy that significantly increases bleeding risk, unless assessed and managed by a physician.
Pregnancy or breastfeeding, as safety has not been established in these populations.
Previous permanent or semi-permanent fillers in the planned treatment area where interactions are uncertain.
Injection into blood vessels, eyelids, glabellar region with high vascular risk, or areas contraindicated by local guidelines for deep HA fillers.

Adverse Effects

Common transient reactions at injection site such as redness (erythema), swelling, pain, tenderness, itching, bruising or slight discolouration.
Temporary lumps, nodules or irregularities in the treated area, often resolving with massage or spontaneously over time.
Local haematoma formation due to vessel injury during injection.
In rare cases, inflammatory reactions (e.g. induration, prolonged swelling) or delayed-type hypersensitivity.
Very rare but serious complications of intravascular injection such as tissue necrosis, visual disturbance, or embolic events; immediate emergency management is required if vascular occlusion is suspected.
Potential reactivation of herpes simplex at injection site in predisposed individuals.
Allergic reactions to lidocaine ranging from local irritation to, very rarely, systemic responses.

Storage Conditions

Store between 2°C and 25°C (do not freeze).
Keep in original packaging to protect from light and contamination.
Do not use if the packaging or syringe is damaged, or if the solution appears cloudy or contains particles.
Do not resterilise; single-use sterile medical device.
Use before the expiry date printed on the carton and syringe label.

Duration

Clinical effect is typically visible immediately after injection and can last approximately 12\u201318 months, depending on individual factors such as metabolism, treatment area and injection technique.

Onset

Volume restoration and wrinkle filling are visible immediately post-injection, with final integration and softening of the result over the following days as the gel settles within the tissue.